CBD Liver Findings in Mice Highlight Dose and Monitoring Concerns

A 2019 study in Molecules examined the potential for a cannabidiol-rich cannabis extract to cause liver injury in mice. The results showed clear toxicity at very high exposures, while also underscoring why CBD’s effects can’t be judged solely by whether users notice immediate symptoms.

Researchers gave eight-week-old male mice either a single oral dose of the extract or daily doses for 10 days. The acute experiment used doses of 246, 738 or 2,460 milligrams per kilogram of body weight. In the longer experiment, animals received 61.5, 184.5 or 615 milligrams per kilogram each day. The researchers described these amounts as mouse-equivalent doses based on the maximum recommended maintenance dose of 20 milligrams per kilogram per day for Epidiolex, the FDA-approved prescription CBD treatment for certain severe seizure disorders.

That comparison requires caution. The experiments used a concentrated cannabis extract—not the same purified formulation used in Epidiolex—and allometric scaling does not mean that a mouse dose is directly equivalent to a human dose. The extract itself contained CBD along with smaller amounts of other cannabinoids.

At the highest single dose, mice became lethargic, ate less and lost some body weight. They also developed biochemical signs associated with liver injury, including elevated alanine aminotransferase (ALT), aspartate aminotransferase (AST) and total bilirubin. Some animals given the intermediate dose showed lethargy and changes in liver-to-body-weight ratios, although the most pronounced blood-test abnormalities occurred at the highest exposure.

The 10-day experiment produced more serious effects at 615 milligrams per kilogram per day. Four of six mice became moribund between the third and fourth days and were euthanized under the study protocol. The remaining two completed the 10-day exposure without visible signs of toxicity. Animals receiving the lower doses did not show obvious outward symptoms, although the researchers reported microscopic changes in liver cells at some exposure levels.

Gene-expression testing added evidence that CBD-rich extract affected biological pathways involved in liver function. More than 50 genes were altered, including genes associated with oxidative stress, lipid metabolism, drug-metabolizing enzymes and other markers of toxicological response. Several of these changes occurred in a dose-dependent pattern.

The findings do not establish that ordinary CBD use causes liver failure, nor do they show that the maximum labeled human dose of Epidiolex is unsafe. Rather, they provide preclinical evidence that sufficiently high CBD exposures can injure the liver and that outward symptoms may not reliably reveal early damage. The study’s lowest tested exposures did not produce the same measurable liver-injury pattern as the highest doses, but that should not be interpreted as proof that all human CBD products are safe.

Human evidence now also points to the importance of monitoring. In a 2025 randomized clinical trial, 201 healthy adults received purified CBD at 5 milligrams per kilogram per day or a placebo for 28 days. Eight of 151 participants in the CBD group—5.6%—developed ALT or AST levels greater than three times the upper limit of normal, compared with none of the 50 placebo participants. The elevations resolved after treatment stopped, and the trial did not report clinically significant liver-function changes, but the results suggest that liver-enzyme abnormalities can occur even at doses closer to those used by some consumers.

For the approved prescription drug, the FDA prescribing information recommends baseline and follow-up testing of ALT, AST and bilirubin. It also warns that the risk of elevated liver enzymes is higher with larger doses and with certain medicines, including valproate. The FDA has separately noted that the safety of widely sold, nonprescription CBD products is harder to assess because their contents, concentrations and labeling may vary.

For consumers, the practical lesson is not that every CBD product is immediately dangerous. It is that dose, duration, product quality, existing liver conditions and interactions with other medicines all matter. Anyone taking CBD regularly—particularly at high doses or alongside prescription medication—should discuss it with a healthcare professional rather than assume that a lack of symptoms rules out liver effects.